OncoLens

12/03/2024

OncoLens has enabled hundreds of breast cancer programs deliver, timely precision cancer care. Whether it is related to finding patients at the right time for germline testing, precision medicine, clinical trials or for quality programs like NAPBC, we are happy to share best practices and lessons learnt. Come talk to us next week!

02/04/2024

OncoLens is excited to announce our participation in Association of Cancer Executives' 30th Annual Meeting in Nashville! We are proud to support and the collaborative efforts of cancer care executives and professionals to improve patient care and outcomes.

We can't wait to catch up with old friends and meet new faces at this year's conference. Be sure to stop by Booth 303 and say hello.

Looking forward to seeing you all there!

10/05/2023

Good Morning from in Austin!

Great to connect with our partner, Dr Joe Kim from QSynthesis

We hope you stop Booth # 605 to meet our team - Seth Schreiber and Chace Herndon

09/26/2023

We're excited to see you at next week. Stop by our booth to discuss strategies to reimagine the delivery of cancer care, including coordinating care across wide provider networks or identifying appropriate clinical trials and biomarker tests, through AI, for your patients.

See you in Austin!

Association of Community Cancer Centers

09/21/2023

Congratulations to UK Markey Cancer Center on this tremendous accomplishment!

The University of Kentucky Markey Cancer Center has earned a National Cancer Institute “Comprehensive” Cancer Center designation, the highest level of recogn...

09/05/2023

Please join us for Session #2 of our expert-led webinar series featuring Dr. Timothy Mullett MD, MBA, FACS, Professor, Division of Cardiothoracic Surgery and Medical Director, University of Kentucky Markey Cancer Center Network Development, as he discusses Lung Cancer Screening and Identification of Patients at all Stages.

When: Wednesday, September 13, 12-1pm EDT

Where: Register here: https://oncolens.zoom.us/webinar/register/WN_a0Po-iBKQ82_kktNmULhTA #/registration

UK Markey Cancer Center

08/21/2023

OncoLens is ranked #316 among 5,000 of the fastest growing private companies in America.

We congratulate our amazing team, supporters, well wishers and most importantly give a big shout out to our customers. We’re honored you’ve chosen us to support your oncology teams as they strive to improve care for cancer patients.

08/11/2023

On July 28, 2023, the Commission on Cancer National Cancer Data Base (NCDB) RCRS introduced updates to three Quality Measures.

Leveraging advancements in Artificial Intelligence (AI) can significantly simplify the process to stay on top of these measures.

Read more about which quality measures have changed and how OncoLens can help: https://www.oncolens.com/blog/strategies-for-enhancing-hospital-programs-accreditation-quality-metric-tracking/

07/27/2023

“Partnering with new sites to build up access in areas with underserved and hard-to-reach patient populations can be largely advantageous for hitting diversity enrollment goals.”

This June 28, 2023 article by the American Association for Cancer Research (AACR) outlines pertinent operational strategies to address Diversity and Inclusion in clinical trials including:

1) Use available data and tools to identify opportunities to enroll and retain diverse patients
2) Expand established partnerships and establish new ones
3) Engage early with sites to align expectations and identify facilitators and challenges to meeting them.

Read the full report here:

https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-23-1391/727437/Driving-Diversity-and-Inclusion-in-Cancer-Drug?searchresult=1

06/21/2023

In this recent study conducted by OncoLens to baseline and improve alignment of biomarker testing to guidelines, top barriers to biomarker testing were: 1) limited quantity of tissue available - 63% of respondents 2) reimbursement concerns including “potential cost to patient,” - 53% of respondents and 3) cumbersome process due to delays and long turnaround times for authorization, ordering, and/or delivery of results - 44% of respondents.
Liquid biopsy which can overcome some of these barriers was a low 4% of testing conducted and required more provider education/engagement. What barriers to do you see to faster market uptake of liquid biopsy?
https://meetings.asco.org/abstracts-presentations/224120

Background: Limited data exists on next-generation sequencing (NGS) testing rates, utilization of single gene tests for therapy matching, use of liquid biopsies in therapy selection, or physician-perceived barriers to testing in hospital-based cancer centers. Initial project goal is to establish a b...